Navigation Links
Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature

PTC124 Targets Nonsense Mutations; Addresses Underlying Cause of Genetic Disorders and Restores Protein Function

SOUTH PLAINFIELD, N.J., April 23, 2007 /PRNewswire/ -- New preclinical data published online in the current edition of the journal Nature show that PTC124, an investigational new drug designed to bypass nonsense mutations, was efficacious in a preclinical model of Duchenne muscular dystrophy (DMD). It is estimated that approximately 13 percent of the cases of DMD are due to nonsense mutations. PTC Therapeutics, Inc., which discovered and is developing PTC124, has catalogued over 1,800 distinct genetic disorders where nonsense mutations are the cause of the disease in a significant percentage of patients. Nonsense mutations inactivate gene function and are known to cause anywhere from five to 70 percent of the individual cases of most inherited diseases, such as cystic fibrosis (10%) and Hurler's syndrome (70%).

"We are pleased that the Nature paper offers an opportunity for us to describe our novel approach to regulating post-transcriptional control processes," said Stuart W. Peltz, Ph.D., President and Chief Executive Officer of PTC Therapeutics. "As these preclinical data demonstrate, the broad potential of PTC124 lies in its specificity and unique mechanism of action, which has the potential to address the underlying cause of a broad range of genetic disorders due to nonsense mutations."

Dr. Peltz continued, "In addition to the ongoing Phase 2 clinical trials of PTC124 in cystic fibrosis and Duchenne muscular dystrophy, we are evaluating PTC124 in a number of additional genetic disorders."

Post-transcriptional control processes are the cellular regulatory events that take place after an RNA molecule is copied from DNA. These processes are critical to proper cellular function and provide an opportunity for therapeutic intervention through the modulation of protein levels.

<
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
2. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
3. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
4. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
5. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
6. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
7. Pieris Demonstrates Potent Anti-Tumor Activity of a VEGF-Specific Anticalin in Preclinical Studies
8. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
9. Waismann Method Survey Reveals Dependency Risk for People Using Suboxone
10. New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace
11. Waismann Method Survey Reveals 65 Percent of Women Seeking Opiate Dependency Treatment Are Mothers
Post Your Comments:
(Date:5/28/2015)...  The recent flurry of PBM mergers and ... scrambling to identify a pharmacy benefit manager that ... retail pharmacy chain, or other potentially conflicting entity. ... Catamaran, Rite Aid,s $2 billion acquisition of EnvisionRx, ... $10 billion are just the latest examples of ...
(Date:5/28/2015)... May 28, 2015   Sanovas, Inc., a rapidly ... the Top 50 Start-Up Companies in the World at the Silicon ... Logo - http://photos.prnewswire.com/prnh/20150528/219097LOGO ... segment experts with direct domain experience screened 2,716 companies from ... Property, Business Model, and Team. This select list was further ...
(Date:5/28/2015)... 28, 2015  Array BioPharma Inc. (NASDAQ: ARRY ... (licensed to AstraZeneca) at the 2015 American Society of ... May 29 – June 2, 2015 in ... advancing in a total of 6 pivotal trials, with ... (binimetinib monotherapy in NRAS mutant melanoma patients) and SUMIT ...
Breaking Medicine Technology:Citizens Rx Addresses Recent PBM Consolidation and Rising Pharmacy Costs 2Citizens Rx Addresses Recent PBM Consolidation and Rising Pharmacy Costs 3Sanovas Awarded Global "Top-50" Start-Up Company 2Sanovas Awarded Global "Top-50" Start-Up Company 3Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting 2Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting 3
... /PRNewswire/ -- Asenapine -- an,investigational drug being developed ... Nobel, for bipolar I disorder and,schizophrenia -- was ... acute manic and mixed episodes associated with bipolar,I ... a study,presented at the American Psychiatric Association's 2007 ...
... Presented at 2007 APA Meeting -, COLLEGEVILLE, ... four new studies examining safety and efficacy ... studied as a potential treatment for adults,with ... at the,2007 American Psychiatric Association annual meeting ...
Cached Medicine Technology:Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 2Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 3Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 2New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 3New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 5New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 6New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 7New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 8
(Date:5/28/2015)... May 28, 2015 CompanionDx ... company, announces that it will present their integrated ... testing at the annual American Society of Clinical ... sequencing evaluates the DNA in a patient’s tumor ... analyzed for key changes or somatic mutations. Pharmacogenomics ...
(Date:5/28/2015)... Beverly Hills, CA (PRWEB) May 28, 2015 ... a novel interactive keratoconus web application to ... Keratoconus has expanded in the last few years. This ... Even eye doctors are not aware of the nuances ... the Khanna Vision Institute, realized that websites can be ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Sexual ... technology that advances sexual health and wellbeing in ... University of San Francisco (USF) will be the ... sexual assault recording and reporting system. , ... transparent, and confidential reporting experience for college sexual ...
(Date:5/28/2015)... DC (PRWEB) May 28, 2015 ... designing and implementing innovative models of care for ... to support alternative reimbursements and help operationalize contracting ... Optimity also unveils a bi-weekly series of seven ... developing Outcomes Based Contracting. Optimity is a strategy, ...
(Date:5/28/2015)... May 28, 2015 Cancer survivors who ... improvements in physical activity, fitness and quality of life, ... Yale Cancer Center and Jennifer Ligibel, MD, senior physician ... Dana Farber Cancer Institute. The findings will be presented ... (ASCO) Annual Meeting in Chicago. , ...
Breaking Medicine News(10 mins):Health News:CompanionDx® Launches Integrated Genomic Solution at ASCO Meeting 2Health News:Dr.Khanna Announced the Release of an Interactive Web Application for Keratoconus Treatment 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 3Health News:Optimity Advisors Now Offers Outcomes Based Contracting Services to Support Engagement Model For New Healthcare Innovative Models of Care 2Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 2Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 3Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 4
... , , , HARRISBURG, ... individuals have received free dental care, valued at nearly $160,000, ... dental insurer United Concordia Dental. , , ... commitment to provide free preventive services to those who cannot ...
... , MIAMI, July 23 Following a ... and a leader in sports nutrition for over 40 years, continues ... weekend Twinlab,s 2009 Mobile Beach Bash ... Miami, Florida. For those eager to show-off their six-pack abs for ...
... , SUNRISE, Fla., July 23 ... delivering intelligent devices and biologics that help monitor, diagnose and ... MARVEL-1 data for presentation at the Heart Failure Society of ... , Chris O,Connor, MD, Head ...
... has shown that risky driving habits are putting young ... of their perceptions about road safety. The study surveyed ... police. Young drivers involved in the study who said ... crash. Previous research has confirmed risky, ...
... Beauty Professionals Encouraged to Share Educational Materials ... , , WASHINGTON, July 23 ... service program created to help women cope with the appearance-related changes of ... Cosmetology Association (NCA) to generate awareness and increase program participation during its ...
... , , , SAN ... OREX ) today announced that it has priced an underwritten ... a price of $7.50 per share. Net proceeds, after estimated ... $70.9 million. Orexigen has granted the underwriter a 30-day option ...
Cached Medicine News:Health News:More than 1,000 Underinsured and Uninsured Individuals Receive Free Dental Care 2Health News:Twinlab's(R) Mobile Beach Bash Heats Up After a Successful Kick-Off of the 2009 RateYourAbs.com Contest 2Health News:Bioheart Announces Acceptance of Marvel-1 Data for Presentation at the Heart Failure Society of America (HFSA) Meeting 2Health News:Bioheart Announces Acceptance of Marvel-1 Data for Presentation at the Heart Failure Society of America (HFSA) Meeting 3Health News:Risky driving puts P-platers at high danger of crash 2Health News:Look Good...Feel Better Launches Salon Awareness Campaign During National Breast Cancer Awareness Month 2Health News:Look Good...Feel Better Launches Salon Awareness Campaign During National Breast Cancer Awareness Month 3Health News:Orexigen(R) Therapeutics Prices Public Offering of Common Stock 2
1.25 mm x 2.5 mm blade. 135 degrees back scratcher. Round handle....
6 mm wide tip. Gentle tapered blade. Designated most popular model or size....
9 mm wide tip. Designated most popular model or size....
4 mm wide tip....
Medicine Products: